Open Actively Recruiting

Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke

About

Brief Summary

This proposal is a prospective, single-center, dose-escalation safety, tolerability, feasibility and potential efficacy study of transcranial direct current stimulation (tDCS) in acute stroke patients with substantial salvageable penumbra due to a large vessel occlusion who are ineligible for intravenous thrombolysis and endovascular therapy.

Primary Purpose
Treatment
Study Type
Interventional
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion criteria:

  • New focal neurologic deficit consistent with AIS
  • NIHSS≥4 or NIHSS <4 in the presence of disabling deficits
  • Age>18;
  • Presence of any cortical vessel occlusion including ICA, branches of MCA, Anterior Cerebral artery (ACA), Posterior Cerebral artery (PCA), Posterior-Inferior cerebellar artery (PICA);
  • Presence of salvageable penumbra with Tmax> 6 sec/ ischemic core volume (ADC < 620 μm2/s or rCBF< 30%) ≥ 1.2
  • Patient ineligible for IV tPA, per national AHA/ASA Guidelines
  • Patient ineligible for endovascular therapy per AHA/ASA national Guidelines - one or more of: poor prestroke functional status (mRS score >1), mild neurological symptoms (NIHSS <6), large ischemic core (ASPECTS <6), thrombectomy not technically performable due to severe vessel tortuosity, cervical artery chronic occlusion, or other unfavorable angioarchitectural features that preclude endovascular access to the target intracranial vessel. 8) Subject is able to be treated with tDCS within 24 hours of last known well time;
  1. A signed informed consent is obtained from the patient or patient's legally authorized representative

Exclusion criteria

  • Acute intracranial hemorrhage
  • Evidence of a large Ischemic core volume (ADC < 620 μm2/s or rCBF< 30%) ≥ 100
  • Presence of tDCS contraindications - electrically or magnetically activated intracranial metal and non-metal implants.
  • Severe MR contrast allergy or renal dysfunction with eGFR<30ml/min, precluding MRI gadolinium or CT iodine contrast
  • Pregnancy
  • Signs or symptoms of acute myocardial infarction, including EKG findings, on admission
  • Suspicion of aortic dissection on admission
  • History of seizure disorder or new seizures with presentation of current stroke
  • Evidence of any other major life-threatening or serious medical condition that would prevent completion of the study protocol including attendance at the 3-month follow-up visit
  • Concomitant experimental therapy
  • Preexisting scalp lesion at the site of the stimulation or presence of skull defects (may alter current flow pattern)
  • Preexisting coagulopathy, consist of platelet count of ≤ 100, INR ≥ 3, PTT ≥ 90.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
18-000421
Category
Neurology
Urology
Principal Investigator
MERSEDEH BAHRHOSSEINI
Contact
Gilda Avila
Location
  • UCLA Westwood
For Providers
NCT No.
NCT03574038
For detailed technical eligibility, visit ClinicalTrials.gov.